• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

B&L shareholders OK Warburg Pincus merger

Article

Bausch & Lomb (B&L) shareholders have approved the proposed merger of the company with affiliates of Warburg Pincus LLC, according to the company.

Rochester, NY-Bausch & Lomb (B&L) shareholders have approved the proposed merger of the company with affiliates of Warburg Pincus LLC, according to the company.

"We look forward to completing the transaction promptly," said Ronald L. Zarrella, B&L chairman and chief executive officer.

The transaction is expected to close early in the fourth quarter. Each outstanding share of B&L common and Class B stock will be canceled and converted into the right to receive $65 in cash, without interest and minus any applicable withholding taxes.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.